Eczema (chronic) - alitretinoin (TA177)
Alitretinoin is recommended as a possible treatment for people with severe chronic hand eczema if:
- their eczema has not improved with treatments called potent topical corticosteroids and
- standard assessments show that their eczema is severe and is affecting their quality of life.
Alitretinoin treatment should be stopped:
- as soon as the eczema has clearly improved or
- if the eczema remains severe after 12 weeks or
- if the eczema has not clearly improved after 24 weeks.
Treatment with alitretinoin should be started and monitored only by doctors who:
- are skin specialists (dermatologists) or
- have experience in both treating people with severe chronic hand eczema and using drugs like alitretinoin.
When assessing how a person’s eczema affects their quality of life, healthcare professionals should take into account any disabilities or difficulties in communicating which might mean that the standard assessments do not provide accurate information.
This page was last updated: 17 June 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA177 Alitretinoin ar gyfer ecsema cronig difrifol y dwylo: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.